SynthesisPloS one2014

Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.

Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.